At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.
Jitka Fučíková, Irena Moserová, Linda Urbanová, Lucillia Bezu, Oliver Kepp, Isabelle Cremer, Cyril Šálek, Pavel Strnad, Guido Guido Kroemer, Lorenzo Galluzzi, Radek Špíšek
Discussion(0)
No comments yet. Be the first to comment.